These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15558044)

  • 21. Post transplant persistence of host cells augments the intensity of acute graft-versus-host disease and level of donor chimerism, an explanation for graft-versus-host disease and rapid displacement of host cells seen following non-myeloablative stem cell transplantation?
    Hirshfeld E; Weiss L; Kasir J; Zeira M; Slavin S; Shapira MY
    Bone Marrow Transplant; 2006 Sep; 38(5):359-64. PubMed ID: 16862165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nephrotic syndrome after allogeneic hematopoietic stem cell transplantation as a late complication of chronic graft-versus-host disease.
    Colombo AA; Rusconi C; Esposito C; Bernasconi P; Caldera D; Lazzarino M; Alessandrino EP
    Transplantation; 2006 Apr; 81(8):1087-92. PubMed ID: 16641591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Keratinocyte growth factor ameliorates acute graft-versus-host disease in a novel nonmyeloablative haploidentical transplantation model.
    Vanclée A; Lutgens LC; Oving EB; Deutz NE; Gijbels MJ; Schouten HC; Bos GM
    Bone Marrow Transplant; 2005 Nov; 36(10):907-15. PubMed ID: 16151417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The changing face of graft-versus-host disease.
    Schaffer JV
    Semin Cutan Med Surg; 2006 Dec; 25(4):190-200. PubMed ID: 17174839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapy.
    Creamer D; Martyn-Simmons CL; Osborne G; Kenyon M; Salisbury JR; Devereux S; Pagliuca A; Ho AY; Mufti GJ; du Vivier AW
    Arch Dermatol; 2007 Sep; 143(9):1157-62. PubMed ID: 17875877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond--the Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation.
    Gorin NC; Labopin M; Boiron JM; Theorin N; Littlewood T; Slavin S; Greinix H; Cahn JY; Alessandrino EP; Rambaldi A; Nagler A; Polge E; Rocha V;
    J Clin Oncol; 2006 Aug; 24(24):3959-66. PubMed ID: 16880451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.
    Rizzieri DA; Koh LP; Long GD; Gasparetto C; Sullivan KM; Horwitz M; Chute J; Smith C; Gong JZ; Lagoo A; Niedzwiecki D; Dowell JM; Waters-Pick B; Liu C; Marshall D; Vredenburgh JJ; Gockerman J; Decastro C; Moore J; Chao NJ
    J Clin Oncol; 2007 Feb; 25(6):690-7. PubMed ID: 17228020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease.
    Yanada M; Naoe T; Iida H; Sakamaki H; Sakura T; Kanamori H; Kodera Y; Okamoto S; Kanda Y; Sao H; Asai O; Nakai K; Maruta A; Kishi K; Furukawa T; Atsuta Y; Yamamoto K; Tanaka J; Takahashi S
    Bone Marrow Transplant; 2005 Nov; 36(10):867-72. PubMed ID: 16113659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
    Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
    Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Second transplant from the same donor without conditioning for bone marrow aplasia after non-myeloablative hematopoietic stem cell transplantation for chronic myeloid leukemia].
    Ishikawa I; Miyamura K; Yamada M; Sasaki O; Harigae H; Kameoka J; Meguro K; Sasaki T
    Rinsho Ketsueki; 2005 Dec; 46(12):1288-92. PubMed ID: 16447801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation.
    Jabbour E; Rondon G; Anderlini P; Giralt SA; Couriel DR; Champlin RE; Khouri IF
    Bone Marrow Transplant; 2007 Sep; 40(5):431-5. PubMed ID: 17603511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Catastrophic antiphospholipid syndrome: atypical presentation in the setting of chronic graft versus host disease: case report and review of the literature.
    Kasamon KM; Drachenberg CI; Rapoport AP; Badros A
    Haematologica; 2005 Mar; 90(3):ECR17. PubMed ID: 15753058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of nonmyeloablative conditioning regimens on the occurrence of pure red cell aplasia after ABO-incompatible allogeneic haematopoietic stem cell transplantation.
    Malfuson JV; Amor RB; Bonin P; Rodet M; Boccaccio C; Pautas C; Kuentz M; Cordonnier C; Noizat-Pirenne F; Maury S
    Vox Sang; 2007 Jan; 92(1):85-9. PubMed ID: 17181595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonmyeloablative and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation: a clinical review.
    Pollack SM; O'Connor TP; Hashash J; Tabbara IA
    Am J Clin Oncol; 2009 Dec; 32(6):618-28. PubMed ID: 19593085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Graft-versus-host disease: case report and review of literature.
    Jing X; Halat S; Meleg-Smith S
    J La State Med Soc; 2006; 158(1):20-4. PubMed ID: 16602481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term outcome after bone marrow transplantation for aplastic anemia using cyclophosphamide and total lymphoid irradiation as conditioning regimen.
    Inamoto Y; Suzuki R; Kuwatsuka Y; Yasuda T; Takahashi T; Tsujimura A; Sugimoto K; Oba T; Terakura S; Atsuta Y; Murata M; Ito M; Kodera Y; Miyamura K
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):43-9. PubMed ID: 18158960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
    Brown JR; Kim HT; Li S; Stephans K; Fisher DC; Cutler C; Ho V; Lee SJ; Milford EL; Ritz J; Antin JH; Soiffer RJ; Gribben JG; Alyea EP
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1056-64. PubMed ID: 17084369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
    Foss FM
    Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.